Market Research Logo

Global PD-1 and PD-L1 Inhibitors Market: Size, Trends and Forecasts (2018-2022)

Global PD-1 and PD-L1 Inhibitors Market: Size, Trends and Forecasts (2018-2022)

Scope of the Report

The report titled “Global PD-1 and PD-L1 Inhibitors Market: Size, Trends and Forecasts (2018-2022)”, provides an in depth analysis of the global PD-1 and PD-L1 inhibitors market by value, by cancer, by treatment, by region, etc. The report also provides a detailed analysis of the China PD-1 and PD-L1 inhibitors market by value, by treatment and by cancer.

The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global PD-1 and PD-L1 Inhibitors market has also been forecasted for the period 2018-2022, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

The global PD-1 and PD-L1 inhibitors market is generally dominated. Many competitors have established worldwide reputation with the multinational patients while some provide their drugs to the domestic patients. The manufacturers of the PD-1 and PD-1 inhibitors market produce different type of drugs, some manufacturers produce PD-1 inhibitors, some produce PD-L1 inhibitors while other produce combination of PD-1 and PD-L1 inhibitors.

However, the competition in the global PD-1 and PD-L1 inhibitors market is dominated by few PD-1 and PD-L1 inhibitors manufacturers. Further, key players of the PD-1 and PD-L1 inhibitors market are Bristol-Myers Squibb, Merck & Co., Inc., Roche, AstraZeneca, Jiangsu Hengrui Medicine Co. Ltd. and BeiGene, Ltd. are also profiled with their financial information and respective business strategies.

Country Coverage

China
The US
ROW

Company Coverage

Bristol-Myers Squibb
Merck & Co., Inc.
Roche
AstraZeneca
Jiangsu Hengrui Medicine Co. Ltd.
BeiGene, Ltd.

Executive Summary

Cancer is the fastest growing disease across the world and one of the most important development in the field of cancer treatment is the introduction of immune checkpoint inhibitors-agents that help to stimulate the immune system. The two main cancer treatment approaches are: Programmed Death-1 (PD-1) and Programmed Death Ligand-1 (PD-L1) inhibitors. PD-1 and PD-L1 inhibitors are both found on the surface of the cancer cells and used to kill cancer cells.

The drugs approved as a PD-1 inhibitor are Pembrolizumab and Nivolumab and the drugs approved as a PD-L1 inhibitors are atezolizumab, Durvalumab and Avelumab. There are various PD-1 and PD-L1 inhibitors which are still in experimental phase of development. The adverse effects of PD-1 and PD-L1 inhibitors are pneumonitis, colitis, skin reactions, immune thrombocytopenia, cardiac insufficiency, diarrhea, pruritus, myocarditis and pneumonitis. PD-1 and PD-L1 inhibitors has a long history with continuously evolving new generation PD-1 and PD-L1 inhibitors. The PD-1 and PD-L1 inhibitors market can be segmented on the basis of type, indications, drug and distribution channel.

The global PD-1 and PD-L1 inhibitors market has increased at a significant annual growth rate during the years 2016-2017 and projections are made that the market would rise in the next four years i.e. 2018-2022 tremendously. The PD-1 and PD-L1 inhibitors market is expected to increase due to aging population, growth in GNI per capita, growing urban population, increasing incidence of certain types of cancer, rise in the number of people with cancer, etc. Yet the market faces some challenges such as high cost of oncology treatment, side effects and toxicity, failure of clinical trials, time consuming and uncertain regulatory process, etc.


1. Executive Summary
2. Introduction
2.1 PD-1 and PD-L1 Inhibitors: An Overview
2.1.1 PD-1 and PD-L1 Inhibitors Discovery Timeline
Table 1: PD-1 and PD-L1 Inhibitors Discovery Timeline
2.1.2 PD-1/PD-L1 Inhibitors Mechanism Action and Applications
Table 2: PD-1/PD-L1 Inhibitors Mechanism Action and Applications
2.1.3 PD-1/PD-L1 Inhibitors in Experimental Phase of Development
Table 3: PD-1/PD-L1 Inhibitors in Experimental Phase of Development
2.1.4 Adverse Effects of PD-1 and PD-L1 Inhibitors
Table 4: Adverse Effects of PD-1 and PD-L1 Inhibitors
2.2 PD-1 and PD-L1 Inhibitors Segmentation: An Overview
2.2.1 PD-1 and PD-L1 Inhibitors by Type
Table 5: PD-1 and PD-L1 Inhibitors by Type
2.2.2 PD-1 and PD-L1 Inhibitors by Indications
Table 6: PD-1 and PD-L1 Inhibitors by Indications
2.2.3 PD-1 and PD-L1 Inhibitors by Drug
Table 7: PD-1 and PD-L1 Inhibitors by Drug
2.2.4 PD-1 and PD-L1 Inhibitors by Distribution Channel
Table 8: PD-1 and PD-L1 Inhibitors by Distribution Channel
3. Global Market Analysis
3.1 Global PD-1 and PD-L1 Inhibitors Market: An Analysis
3.1.1 Global PD-1 and PD-L1 Inhibitors Market by Value
Table 9: Global PD-1 and PD-L1 Inhibitors Market by Value; 2016-2017 (US$ Billion)
Table 10: Global PD-1 and PD-L1 Inhibitors Market by Value; 2018-2022 (US$ Billion)
3.1.2 Global PD-1 and PD-L1 Inhibitors Market by Segments (Metastatic PD-1 and PD-L1 Inhibitors and Adjuvant PD-1 and PD-L1 Inhibitors)
Table 11: Global PD-1 and PD-L1 Inhibitors Market by Segments; 2017
(Percentage, %)
3.1.3 Global PD-1 and PD-L1 Inhibitors Market by Region (The US, China and ROW)
Table 12: Global PD-1 and PD-L1 Inhibitors Market by Region; 2017-2018 (Percentage, %)
3.2 Global PD-1 and PD-L1 Inhibitors Market: Segment Analysis
3.2.1 Global Metastatic PD-1 and PD-L1 Inhibitors Market by Value
Table 13: Global Metastatic PD-1 and PD-L1 Inhibitors Market by Value; 2016-2017
(US$ Billion)
Table 14: Global Metastatic PD-1 and PD-L1 Inhibitors Market by Value; 2018-2022
(US$ Billion)
3.2.2 Global Adjuvant PD-1 and PD-L1 Inhibitors Market by Value
Table 15: Global Adjuvant PD-1 and PD-L1 Inhibitors Market by Value; 2017-2022 (US$ Billion)
4. Regional Market Analysis
4.1 China PD-1 and PD-L1 Inhibitors Market: An Analysis
4.1.1 China PD-1 and PD-L1 Inhibitors Market by Value
Table 16: China PD-1 and PD-L1 Inhibitors Market by Value; 2018-2022 (US$ Billion)
4.1.2 China PD-1 and PD-L1 Inhibitors Market by Cancer (Non-small Cell Lung Carcinoma, Hepatocellular Carcinoma, Gastric Cancer, Esophageal Cancer, Small Cell Lung Cancer and Others)
Table 17: China PD-1 and PD-L1 Inhibitors Market by Cancer; 2018 & 2022 (Percentage, %)
4.1.3 China PD-1 and PD-L1 Inhibitors Market by Treatment (1L Treatment and 2L+ Treatment)
Table 18: China PD-1 and PD-L1 Inhibitors Market by Treatment; 2018
(Percentage, %)
4.2 China PD-1 and PD-L1 Inhibitors Market: Treatment Analysis
4.2.1 China 1L PD-1 and PD-L1 Inhibitors Market by Value
Table 19: China 1L PD-1 and PD-L1 Inhibitors Market by Value; 2018-2022
(US$ Billion)
4.2.2 China 1L PD-1 and PD-L1 Inhibitors Market by Cancer (Non-small Cell Lung Carcinoma, Hepatocellular Carcinoma, Gastric Cancer, Esophageal Cancer, Small Cell Lung Cancer and Others)
Table 20: China 1L PD-1 and PD-L1 Inhibitors Market by Cancer; 2018
(Percentage, %)
4.2.3 China 2L+ PD-1 and PD-L1 Inhibitors Market by Value
Table 21: China 2L+ PD-1 and PD-L1 Inhibitors Market by Value; 2018-2022
(US$ Million)
4.2.4 China 2L+ PD-1 and PD-L1 Inhibitors Market by Cancer (Non-small Cell Lung Carcinoma, Hepatocellular Carcinoma, Gastric Cancer, Esophageal Cancer, Small Cell Lung Cancer and Others)
Table 22: China 2L+ PD-1 and PD-L1 Inhibitors Market by Cancer; 2018 (Percentage, %)
4.3 China PD-1 and PD-L1 Inhibitors Market: Cancer Analysis
4.3.1 China Non-small Cell Lung Cancer (NSCLC) Market by Value
Table 23: China Non-small Cell Lung Cancer (NSCLC) Market by Value; 2018-2022 (US$ Billion)
4.3.2 China Non-small Cell Lung Cancer (NSCLC) Market by Treatment (1L Treatment and 2L+ Treatment)
Table 24: China Non-small Cell Lung Cancer (NSCLC) Market by Treatment; 2018 (Percentage, %)
4.3.3 China 1L and 2L+ Non-small Cell Lung Cancer (NSCLC) Treatment Market by Value
Table 25: China 1L Non-small Cell Lung Cancer (NSCLC) Treatment Market by Value; 2018-2022 (US$ Billion)
Table 26: China 2L+ Non-small Cell Lung Cancer (NSCLC) Treatment Market by Value; 2018-2022 (US$ Million)
4.3.4 China Small Cell Lung Cancer (SCLC) Market by Value
Table 27: China Small Cell Lung Cancer (SCLC) Market by Value; 2018-2022
(US$ Million)
4.3.5 China Small Cell Lung Cancer (SCLC) Market by Treatment (1L Treatment and 2L+ Treatment)
Table 28: China Small Cell Lung Cancer (SCLC) Market by Treatment; 2018 (Percentage, %)
4.3.6 China 1L and 2L+ Small Cell Lung Cancer (SCLC) Treatment Market by Value
Table 29: China 1L Small Cell Lung Cancer (SCLC) Treatment Market by Value;
2018-2022 (US$ Million)
Table 30: China 2L+ Small Cell Lung Cancer (SCLC) Treatment Market by Value;
2018-2022 (US$ Million)
4.3.7 China Hepatocellular Carcinoma (HCC) Market by Value
Table 31: China Hepatocellular Carcinoma (HCC) Market by Value; 2018-2022
(US$ Million)
4.3.8 China Hepatocellular Carcinoma (HCC) Market by Treatment (1L Treatment and 2L+ Treatment)
Table 32: China Hepatocellular Carcinoma (HCC) Market by Treatment; 2018 (Percentage, %)
4.3.9 China 1L and 2L+ Hepatocellular Carcinoma (HCC) Treatment Market by Value
Table 33: China 1L Hepatocellular Carcinoma (HCC) Treatment Market by Value;
2018-2022 (US$ Million)
Table 34: China 2L+ Hepatocellular Carcinoma (HCC) Treatment Market by Value; 2018-2022 (US$ Million)
4.3.10 China Gastric Cancer (GC) Market by Value
Table 35: China Gastric Cancer (GC) Market by Value; 2018-2022 (US$ Million)
4.3.11 China Gastric Cancer (GC) Market by Treatment (1L Treatment and 2L+ Treatment)
Table 36: China Gastric Cancer (GC) Market by Treatment; 2018 (Percentage, %)
4.3.12 China 1L and 2L+ Gastric Cancer (GC) Treatment Market by Value
Table 37: China 1L Gastric Cancer (GC) Treatment Market by Value; 2018-2022
(US$ Million)
Table 38: China 2L+ Gastric Cancer (GC) Treatment Market by Value; 2018-2022
(US$ Million)
4.3.13 China Esophageal Squamous Cell Carcinoma (ESCC) Market by Value
Table 39: China Esophageal Squamous Cell Carcinoma (ESCC) Market by Value;
2018-2022 (US$ Million)
4.3.14 China Esophageal Squamous Cell Carcinoma (ESCC) Market by Treatment (1L Treatment and 2L+ Treatment)
Table 40: China Esophageal Squamous Cell Carcinoma (ESCC) Market by Treatment; 2018 (Percentage, %)
4.3.15 China 1L and 2L+ Esophageal Squamous Cell Carcinoma (ESCC) Treatment Market by Value
Table 41: China 1L Esophageal Squamous Cell Carcinoma (ESCC) Treatment Market by Value; 2018-2022 (US$ Million)
Table 42: China 2L+ Esophageal Squamous Cell Carcinoma (ESCC) Treatment Market by Value; 2018-2022 (US$ Million)
4.3.16 China Other Cancers Market by Value
Table 43: China Other Cancers Market by Value; 2018-2022 (US$ Million)
4.3.17 China Other Cancers Market by Treatment (1L Treatment and 2L+ Treatment)
Table 44: China Other Cancers Market by Treatment; 2018 (Percentage, %)
4.3.18 China 1L and 2L+ Other Cancers Treatment Market by Value
Table 45: China 1L Other Cancers Treatment Market by Value; 2018-2022
(US$ Million)
Table 46: China 2L+ Other Cancers Treatment Market by Value; 2018-2022
(US$ Million)
4.4 The US PD-1 and PD-L1 Inhibitors Market: An Analysis
4.4.1 The US PD-1 and PD-L1 Inhibitors Market by Value
Table 47: The US PD-1 and PD-L1 Inhibitors Market by Value; 2016-2017 (US$ Billion)
Table 48: The US PD-1 and PD-L1 Inhibitors Market by Value; 2018-2022 (US$ Billion)
4.5 ROW PD-1 and PD-L1 Inhibitors Market: An Analysis
4.5.1 ROW PD-1 and PD-L1 Inhibitors Market by Value
Table 49: ROW PD-1 and PD-L1 Inhibitors Market by Value; 2016-2017 (US$ Billion)
Table 50: ROW PD-1 and PD-L1 Inhibitors Market by Value; 2018-2022 (US$ Billion)
5. Market Dynamics
5.1 Growth Driver
5.1.1 Aging Population
Table 51: World Aging Population by Gender ; 2011-2017 (Trillion)
5.1.2 Increasing GNI Per Capita
Table 52: Global GNI Per Capita; 2010-2016 (US$)
5.1.3 Growing Urban Population
Table 53: Global Urban Population; 2011-2017 (Billion)
5.1.4 Increased Incidence of Certain Types of Cancer
Table 54: Incidence of Certain Types of Cancer; 2017
5.1.5 Surge in the Number of People with Cancer by Age
Table 55: Number of People with Cancer by Age; 2011-2016 (Million)
5.2 Challenges
5.2.1 High Cost of Oncology Treatment
Table 56: Global Oncology Treatment Cost; 2012-2016 (US$ Billion)
5.2.2 Side Effects and Toxicity
5.2.3 Failure of Clinical Trial
5.2.4 Time Consuming and Uncertain Regulatory Process
5.3 Market Trends
5.3.1 Rising Healthcare Awareness and Changing Lifestyle
5.3.2 Public Medical Insurance
5.3.3 Accelerated Approval of New PD-1 and PD-L1 Inhibitors
Table 57: Approved PD-1 and PD-L1 inhibitors Timeline; 2017
5.3.4 Increased Consumption of Alcohol and Smoking
6. Competitive Landscape
6.1 Global PD-1 and PD-L1 Inhibitors Market: Competitive Landscape
Table 58: Global PD-1 and PD-L1 Inhibitors Market: Competitive Landscape
6.2 Global PD-1 and PD-L1 Inhibitors Market Players by Phase 3 Studies
Table 59: Global PD-1 and PD-L1 Inhibitors Market Players by Phase 3 Studies; 2017 (Percentage, %)
6.3 Regulatory Status of Key PD-L1 Drugs in China
Table 60: Regulatory Status of Key PD-L1 Drugs in China
7. Company Profiles
7.1 Bristol-Myers Squibb
7.1.1 Business Overview
7.1.2 Financial Overview
Table 61: Bristol-Myers Squibb Total Revenue; 2013-2017 (US$ Billion)
Table 62: Bristol-Myers Squibb Total Revenue by Products; 2017 (Percentage, %)
Table 63: Bristol-Myers Squibb Total Revenue by Region; 2017 (Percentage, %)
7.1.3 Business Strategy
7.2 Merck & Co., Inc.
7.2.1 Business Overview
7.2.2 Financial Overview
Table 64: Merck & Co. Inc. Sales; 2013-2017 (US$ Billion)
Table 65: Merck & Co. Inc. Sales by Segment; 2017 (Percentage, %)
Table 66: Merck & Co. Inc. Sales by Region; 2017 (Percentage, %)
7.2.3 Business Strategy
7.3 Roche
7.3.1 Business Overview
7.3.2 Financial Overview
Table 67: Roche Sales; 2013-2017 (US$ Billion)
Table 68: Roche Sales by Segments; 2017 (Percentage,%)
Table 69: Roche Sales by Region; 2017 (Percentage, %)
7.3.3 Business Strategy
7.4 AstraZeneca
7.4.1 Business Overview
7.4.2 Financial Overview
Table 70: AstraZeneca Total Revenue; 2013-2017 (US$ Billion)
Table 71: AstraZeneca Total Revenue by Region; 2017 (Percentage, %)
7.4.3 Business Strategy
7.5 Jiangsu Hengrui Medicine Co. Ltd.
7.6 BeiGene, Ltd.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report